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The articles in this issue of the International Journal of Technology Assessment in
Health Care (IJTAHC) have explored the assessment of preventive health technolo-
gies. When considered together, these technologies provide an interesting contrast with
the health care technologies that are usually evaluated on these pages. Disease preven-
tion and its twin, health promotion, are usually practiced on a well population. Thus,
many persons have the technology applied to them but only a fraction of these would
have acquired the condition being prevented. Often the intervention is applied to popu-
lations rather than to individuals. The unit cost for preventive technologies is usually
far less than that of diagnostic or therapeutic technologies. However, when multiplied
by the larger population to be involved in the prevention program, the total costs can
be considerable. In concluding this section on prevention, we would like to examine
some of the larger areas of difference between preventive and other health technolo-
gies illustrated by the papers assembled here.
Screening. The early detection of disease is far more complex than merely having
a screening test that is accurate, consistent, and inexpensive. Although sensitivity and
specificity may be high, prevalence of the condition to be detected is an important
variable because it is a critical determinant of positive predictive value. The impor-
tance we attach to false positivity and false negativity also varies by the condition.
All these points are well illustrated by Rosenbrock in his consideration of HIV screening
(11). The impact of a false-positive HIV test result can be psychologically devastating.
A false-negative result, at a minimum, denies the person being screened information
needed for planning. Even more, a false-negative result may interfere with prompt ap-
propriate therapy and fail to motivate behaviors that will reduce risk of transmission
to others. In addition, HIV screening raises the issue of the linkage between early de-
tection and effective treatment or management. A prerequisite of a screening program
is that it leads to a change in treatment and an improved outcome (4;8). Does a positive
or negative HIV screening result alter the behavioral recommendations to avoid activi-
ties that increase risk to the person being screened or to others? Do we have effective
and cost-effective treatments for which early detection of HIV positivity would be
valuable? Because screening is applied to a broad population, it requires a broader
use, available at https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0266462300005730
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 17:08:12, subject to the Cambridge Core terms of
Koplan and Gutzwiller
approach than simple diagnostic testing. Ethical, legal, psychosocial, economic, and
epidemiologic issues must be considered.
Assessment in Populations Rather Than Individuals. Many prevention pro-
grams are public health programs and, as such, are targeted to communities. In such
programs, assessment can focus on the relative benefits, risks, and costs to the individual
or to the community (10). Both analyses are useful and may yield quite different con-
clusions. Thus, we assess a particular vaccine for use in a given set of circumstances
for an individual or look at the value of the same vaccine when used in a community-
wide vaccination program. Variables such as the rates of untoward sequelae of a vac-
cine, the incidence of disease, who pays the cost of the vaccine and the disease, the
severity and importance of a given immunizable disease for different subpopulations,
the contribution of herd immunity, etc., may lead to different conclusions for the in-
dividual or for the community.
For community prevention program assessments, surveillance is a vital prerequi-
site (12). Surveillance of disease rates, health care practices, risk factors, or surrogates
(alcohol sales) is necessary to identify problems, set policies, plan programs, and es-
tablish the baseline for subsequent evaluation efforts. Thus, in order to assess hepatitis-B
immunization programs in Greece (5), we need to know the rate of hepatitis-B infec-
tion for various subpopulations. To determine the value of school health education
programs, we need to know the rates of smoking and other behaviors in schoolchil-
dren before, during, and after the intervention. In addition, as with other technologies
aimed at long-term influence on behavior, such as dietary change (13) or tobacco con-
trol (7), we need to continue routine surveillance long after the termination of an inter-
vention.
Another aspect of preventive technologies applied to a community is their relative
complexity compared to diagnostic or therapeutic technologies for an individual. A
community program may be more focal, such as fluoridation of the public water system
(2), but frequently involves a variety of multidisciplinary activities. Thus, Chorba (1)
describes using the technological devices of motor vehicle passenger restraints in the
larger context of legislation, enforcement of that legislation, environmental manipu-
lation, penalties, and public knowledge and attitudes. Similarly, Mackay and Davis
(7) consider the features of successful antismoking programs and, at a minimum, list
education of the public, the government, health professionals, and the media; increased
taxation; curtailed advertisements; restricted smoking areas; blunt package warnings;
school health education; and mass communication campaigns. Changing dietary pat-
terns as summarized by Vartiainen et al. (13) for cardiovascular disease prevention pro-
grams requires intervening with the food industry, providing health education, ad-
dressing the accessibility of healthy dietary choices, and linking various components
of a heart-healthy lifestyle. Such a multiplicity of approaches greatly complicates as-
sessment. Attempts to isolate one component of such a program are occasionally suc-
cessful, such as the ability to document the effectiveness of antismoking components
of school health education (3). However, more frequently we are left with the impres-
sion that all the components work symbiotically or at least in a complementary fashion
to produce the desired effect (1;7).
Similarly, the outcomes themselves can be difficult to measure in a community
program. Process measures or intermediary outcomes may serve to substitute for "ul-
timate" outcomes. Thus, knowing the well-established link between smoking and lung
cancer deaths, we need not wait 20 years to measure lung cancer mortality, but rather
can measure smoking rates to assess our program's effectiveness. While Mackay and
Davis argue that the cigarette industry's responses are a measure of an antismoking
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program's effectiveness, this form of assessment may be too indirect for many evalu-
ators. In the case of motor vehicle collision fatalities, a health condition with a shorter
latency period, prevalence of safety belt use may be a useful surveillance measure, but
it can be relatively easily coupled with mortality data.
Community prevention programs are also often complicated by having more than
one health outcome. Thus, antismoking programs can consider all the adverse health
outcomes caused by tobacco: lung cancer, oral cancer, coronary heart disease, chronic
obstructive lung disease, etc. In contrast, what is arguably one of the most effective
and cost-effective prevention programs, community water fluoridation, has relatively
easily measurable outcomes: decayed, missing, or filled teeth, the DMF index (2).
Technology Assessment and Public Policy. Because public health programs
involve an explicit expenditure of public funds, community prevention efforts have
long been held up to scrutiny and evaluated in a way that therapeutic interventions
have not. Thus, there is a long history of drugs, devices, and surgical procedures being
widely implemented with little assessment, and then restricted over time as assessments
are performed. Prevention technologies are judged for safety, effectiveness, and cost-
effectiveness early in their development. Vaccine programs illustrate such a logical pro-
cess, as seen in the stepwise increases in hepatitis-B vaccine use worldwide. HIV
screening, injury control, fluoridation, school health education, and smoking preven-
tion programs have all been the subject of public debate and professional study, with
the subsequent consideration of the broad range of concerns that make up technology
assessment. Clinical health technologies rarely are subjected to such scrutiny—be they
electronic fetal monitoring, surgery for coronary heart disease, or hysterectomy (6;9).
Preventive approaches are usually preferable to the clinical alternatives, both con-
ceptually and in terms of consumer satisfaction. This is not to say that all preventive
approaches are effective, or cost-saving, or even cost-effective relative to other ap-
proaches. Nevertheless, preventive technologies offer much as a way to avert suffering,
disability, death, and health care costs. Health care professionals interested in tech-
nology assessment should apply their skills to health promotion and disease preven-
tion technologies to more widely diffuse those that are found to be effective, to limit
those that are not, and to better define the circumstances under which the technolo-
gies should be used.
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